文献速递眼底病与葡萄膜炎

抗VEGF治疗期间新生血管性年龄相关性黄斑变性患者脉络膜毛细血管血管密度降低

Reduced Vessel Density of the Choriocapillaris during Anti-Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2019-01-01

回顾性研究纳入124眼长期抗VEGF单药治疗的新生血管性年龄相关性黄斑变性(nAMD)患者,利用OCTA评估黄斑血管改变。随访14.5±3.1个月后,深层毛细血管丛(DCP)和脉络膜毛细血管(CC)血管密度显著下降(P=0.001和P=0.009),而63只对照眼未见此变化。结论提示长期抗VEGF治疗期间DCP和CC恶化,需保护毛细血管以维持视力。

要点

  • 长期抗VEGF治疗的nAMD眼OCTA显示DCP和CC血管密度显著降低。
  • 对照眼未观察到DCP和CC血管密度的显著下降。
  • 需前瞻性对照试验确认 findings,并考虑保护毛细血管的治疗策略。

核心结论

  • 长期抗VEGF治疗期间,nAMD眼的深层毛细血管丛和脉络膜毛细血管血管密度显著下降。

研究设计与样本

  • 回顾性研究,纳入124例日本nAMD患者(124眼),均有长期抗VEGF单药治疗史,采用OCTA计算血管密度。

主要发现

  • DCP血管密度从10.62±2.72 mm-1降至9.44±2.88 mm-1(P=0.001)。
  • CC血管密度从11.84±1.79 mm-1降至11.18±2.12 mm-1(P=0.009)。
  • 63只对照眼未观察到上述血管密度下降。

关键数值与推荐

  • 首次至末次OCTA成像平均随访14.5±3.1个月。
  • 首次OCTA前抗VEGF单药治疗 duration 为68.0±23.6个月,随访期间平均注射3.6±3.0次。

临床怎么用

  • 长期抗VEGF治疗nAMD时需关注DCP和CC血管密度下降,可能需保护毛细血管以维持视力。

局限性

  • 回顾性设计,需前瞻性对照试验确认 findings。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate macular vascular alterations by using optical coherence tomography angiography (OCTA) in patients with a history of long-term anti-vascular endothelial growth factor (VEGF) therapy for neovascular age-related macular degeneration (nAMD). METHODS: Japanese patients with nAMD with a history of long-term anti-VEGF monotherapy at study entry were studied retrospectively. OCTA images were obtained, and the vessel densities (mm-1) of the superficial capillary plexus, deep capillary plexus (DCP), choriocapillaris (CC), and the plexus foveal avascular zone area (mm2) were calculated. RESULTS: One hundred twenty-four eyes (124 patients) were included. The mean ± standard deviation follow-up period between the first and last OCTA imaging sessions was 14.5 ± 3.1 months; the duration of the anti-VEGF monotherapy before the first OCTA imaging session was 68.0 ± 23.6 months, with a mean of 3.6 ± 3.0 injections during the follow-up period. The vessel densities of the DCP and CC significantly decreased (P = 0.001 and P = 0.009, respectively) from 10.62 ± 2.72 mm-1 and 11.84 ± 1.79 mm-1 to 9.44 ± 2.88 mm-1 and 11.18 ± 2.12 mm-1. Such findings were not observed in 63 control eyes. CONCLUSIONS: The DCP and CC deteriorate during treatment. This information may guide future treatment strategies for nAMD, such as the need to protect the capillaries to maintain visual acuity after long-term treatment. Prospective, controlled trials are required to confirm our findings.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Hikichi T, Agarie M. Reduced Vessel Density of the Choriocapillaris during Anti-Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. 2019. PMID: 30901385. doi:10.1167/iovs.18-24522

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。